BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 32457491)

  • 1. Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.
    Ryu WJ; Lee JD; Park JC; Cha PH; Cho YH; Kim JY; Sohn JH; Paik S; Choi KY
    Exp Mol Med; 2020 May; 52(5):832-842. PubMed ID: 32457491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
    Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
    Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
    Shen H; Yan W; Yuan J; Wang Z; Wang C
    J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.
    Capasso A; Bagby SM; Dailey KL; Currimjee N; Yacob BW; Ionkina A; Frank JG; Kim DJ; George C; Lee YB; Benaim E; Gittleman B; Hartman SJ; Tan AC; Kim J; Pitts TM; Eckhardt SG; Tentler JJ; Diamond JR
    Mol Cancer Ther; 2019 Nov; 18(11):1916-1925. PubMed ID: 31488700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saikosaponin D from Radix Bupleuri suppresses triple-negative breast cancer cell growth by targeting β-catenin signaling.
    Wang J; Qi H; Zhang X; Si W; Xu F; Hou T; Zhou H; Wang A; Li G; Liu Y; Fang Y; Piao HL; Liang X
    Biomed Pharmacother; 2018 Dec; 108():724-733. PubMed ID: 30248540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
    Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA
    PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation.
    Shome R; Ghosh SS
    Cell Oncol (Dordr); 2021 Apr; 44(2):405-422. PubMed ID: 33398673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual targeting of Notch and Wnt/β-catenin pathways: Potential approach in triple-negative breast cancer treatment.
    Nasser F; Moussa N; Helmy MW; Haroun M
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Mar; 394(3):481-490. PubMed ID: 33052427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule-induced simultaneous destabilization of β-catenin and RAS is an effective molecular strategy to suppress stemness of colorectal cancer cells.
    Cho YH; Ro EJ; Yoon JS; Kwak DK; Cho J; Kang DW; Lee HY; Choi KY
    Cell Commun Signal; 2020 Mar; 18(1):38. PubMed ID: 32143715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous destabilization of β-catenin and Ras via targeting of the axin-RGS domain as a potential therapeutic strategy for colorectal cancer.
    Cha PH; Choi KY
    BMB Rep; 2016 Sep; 49(9):455-6. PubMed ID: 27470214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H3K27ac-induced RHOXF2 activates Wnt2/β-catenin pathway by binding to HOXC13 to aggravate the malignant progression of triple negative breast cancer.
    Guo M; Wang R; Nie M; Zhang H; Wang C; Song C; Niu S
    Cell Signal; 2024 Aug; 120():111196. PubMed ID: 38697448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.
    Li Y; Xiao Y; Lin HP; Reichel D; Bae Y; Lee EY; Jiang Y; Huang X; Yang C; Wang Z
    Biomaterials; 2019 Jan; 188():160-172. PubMed ID: 30352320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
    Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
    Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway.
    Xie W; Zhao H; Wang F; Wang Y; He Y; Wang T; Zhang K; Yang H; Zhou Z; Shi H; Wang J; Huang G
    J Exp Clin Cancer Res; 2021 Jan; 40(1):30. PubMed ID: 33436039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
    Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
    Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
    Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
    Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
    Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.
    De P; Carlson JH; Jepperson T; Willis S; Leyland-Jones B; Dey N
    Oncotarget; 2017 Jan; 8(2):3072-3103. PubMed ID: 27902969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer.
    Gangrade A; Pathak V; Augelli-Szafran CE; Wei HX; Oliver P; Suto M; Buchsbaum DJ
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation.
    Cha PH; Cho YH; Lee SK; Lee J; Jeong WJ; Moon BS; Yun JH; Yang JS; Choi S; Yoon J; Kim HY; Kim MY; Kaduwal S; Lee W; Min do S; Kim H; Han G; Choi KY
    Nat Chem Biol; 2016 Aug; 12(8):593-600. PubMed ID: 27294323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.